This webcast features: Thomas Page, PhD, Vice President, Engineering and Asset Development, FUJIFILM Diosynth Biotechnologies![FDB-11-7-19-ATE-300x300.png FDB-11-7-19-ATE-300x300.png](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt5b7f6fbdd40c4088/658ca4fd893dc8040a9fcee4/FDB-11-7-19-ATE-300x300.png?width=700&auto=webp&quality=80&disable=upscale)
Fujifilm Diosynth Biotechnologies (FDB) sought to “close the loop” by keeping all upstream and downstream aseptic processing operations within closed systems. The missing part was downstream, where FDB implemented a closed robotic filling workcell for manufacturing gene therapies.
Workcells solve long-standing problems with sterility assurance, containment, and process control in aseptic filling. The knowledge developed by FDB during its implementation and early use of a closed workcell can benefit organizations developing new drug products.
Participants will learn about the following topics:
– Transitioning to a fully closed, robotically driven aseptic filling process
– Removing humans from the process for “touchless” filling
– Managing hazard pathways and risks to drug products
– Ensuring “closure by design” for product safety and vial integrity
Watch the recorded webcast below.